AI assistant
Sending…
Biohit Oyj — Director's Dealing 2017
Aug 22, 2017
3304_rns_2017-08-22_c7b6bf37-9bb9-4f45-bd26-b552437a0a9f.html
Director's Dealing
Open in viewerOpens in your device viewer
Biohit Oyj - Managers' Transactions
Biohit Oyj - Managers' Transactions
Biohit Oyj - Managers' Transactions, August 22, 2017 at 1:50 pm local time (EEST)
Biohit Oyj has received the following notification.
| Person subject to the notification requirement | ||
| Name: | Korpela, Semi | |
| Position: | Chief Executive Officer | |
| Initial Notification | ||
| Reference number: | 74370089ATTSNBXJVT29_20170822114218_4 | |
| Issuer | ||
| Name: | Biohit Oyj | |
| LEI: | 74370089ATTSNBXJVT29 | |
| Transaction details | ||
| Transaction date: | 2017-08-17 | |
| Venue: | NASDAQ HELSINKI LTD (XHEL) | |
| Nature of the transaction: | Disposal | |
| Instrument: | Share | |
| ISIN: | FI0009005482 | |
| Volume: | 500 | |
| Unit price: | 5,51000 Euro | |
| Volume: | 100 | |
| Unit price: | 5,51000 Euro | |
| Volume: | 38 | |
| Unit price: | 5,52000 Euro | |
| Volume: | 300 | |
| Unit price: | 5,51000 Euro | |
| Volume: | 50 | |
| Unit price: | 5,50000 Euro | |
| Volume: | 129 | |
| Unit price: | 5,50000 Euro | |
| Volume: | 500 | |
| Unit price: | 5,50000 Euro | |
| Volume: | 175 | |
| Unit price: | 5,49000 Euro | |
| Volume: | 36 | |
| Unit price: | 5,49000 Euro | |
| Volume: | 588 | |
| Unit price: | 5,49000 Euro | |
| Volume: | 822 | |
| Unit price: | 5,49000 Euro | |
| Volume: | 36 | |
| Unit price: | 5,49000 Euro | |
| Volume: | 36 | |
| Unit price: | 5,49000 Euro | |
| Volume: | 103 | |
| Unit price: | 5,50000 Euro | |
| Volume: | 178 | |
| Unit price: | 5,49000 Euro | |
| Volume: | 35 | |
| Unit price: | 5,49000 Euro | |
| Volume: | 484 | |
| Unit price: | 5,49000 Euro | |
| Aggregated transactions | ||
| Volume: | 4110 | |
| Volume weighted average price: | 5.49656 Euro |
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com